Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012
Phase of Trial: Phase IV
Latest Information Update: 14 Apr 2017
At a glance
- Drugs Golimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms GO-EASY
- Sponsors Merck & Co; Merck Sharp & Dohme
- 12 May 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
- 14 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 15 Aug 2012 Merck added as trial sponsor and lead trial centre as reported by ClinicalTrials.gov.